• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Opinion

Video

JAK Inhibitor Overview and Relevance to AD

Author(s):

Christopher G. Bunick, MD, PhD,Ruth Ann Vleugels, MD, MPH, MBA

Christopher Bunick, MD, PhD, and Ruth Ann Vleugels, MD, MPD, MBA, discuss the method of action for Janus Kinase (JAK) inhibitors and the pathology of atopic dermatitis (AD).

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Related Content
Concerto Biosciences Doses First Participant in Phase 1 Trial of ENS-002, a Microbiome-Based Therapy for Atopic Dermatitis
November 20th 2024

Concerto Biosciences Doses First Participant in Phase 1 Trial of ENS-002, a Microbiome-Based Therapy for Atopic Dermatitis

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
August 2nd 2024

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Matthew Zirwas, MD: Cutting-Edge Advances in Atopic Dermatitis and Itch Management
November 15th 2024

Matthew Zirwas, MD: Cutting-Edge Advances in Atopic Dermatitis and Itch Management

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
July 1st 2024

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

PDUFA Date for Tapinarof 1% Cream in Atopic Dermatitis Pushed to 2025
November 5th 2024

PDUFA Date for Tapinarof 1% Cream in Atopic Dermatitis Pushed to 2025

Off-Treatment Remission Achieved with Dupilumab for Pediatric AD
November 4th 2024

Off-Treatment Remission Achieved with Dupilumab for Pediatric AD

© 2024 MJH Life Sciences

All rights reserved.